A method to identify the presence of heavy metals in pharmaceuticals was introduced in the United States Pharmacopoeia more than 100 years ago. Today pharmaceutical companies are still using essentially the same method, the USP <231> Heavy Metals Limit Test. This paper will give an overview of the current method limitations, considerations for the new methodology and the risk-based assessments being carried out by manufacturers.
- Elemental Impurity Analysis in Pharmaceuticals – The Road To Implementation of ICH Q3D
- Excellence in Pharmaceutical Analysis
- Enhanced Sampling and Calibration Procedures for the Analysis of Residual Oxygen in Nitrogen Purged Pharmaceutical Packaging by GC-TCD
- Enhanced Residual Solvents Analysis: A Practical Approach to Sampling, Delivery, Storage and Analysis.